Van Buren views Regeneron's psoriasis drug Dupixent as being "one of the largest drugs in biotech and pharmaceuticals” which could bring in revenue of $21 billion by 2027.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The company’s shares closed yesterday at $686.33 ...

Tyler Van Buren. But the Regeneron is in the enviable position of having now $16 billion of cash, I believe, generating probably about five this year. It's only getting larger.

TD Cowen has named biotech company Regeneron (REGN) the best idea for 2024. TD Cowen Senior Biotech Equity Tyler Van Buren joins Yahoo Finance Live to break down the details of this call. Van Buren, ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $970.00. See what stocks are receiving Strong Buy ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Cowen 43rd Annual Health Care Conference March 6, 2023 12:50 PM ETCompany ParticipantsMarion McCourt ... Tyler Van Buren - Cowen.